Etanercept (Enbrel)

Etanercept is used to treat

  • Rheumatoid arthritis
  • Plaque psoriasis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Polyarticular juvenile idiopathic arthritis (JIA)

- It is an anti-TNF biologic that differs from adalimumab and Infliximab, as it contains a TNFR2 structure to bind TNF instead of a classical Fab antibody segment

- It is administered through subcutaneous injection once a week.

- In 2016, €1.6 billion was spent on this drug in Europe.

- It has an immunogenicity rate of 3-6%.

Labs that test for drug level: 

Karolinska Univeristy Lab
Lab University of Tours
KU Leuven

Labs that test for ADA titre: 

Karolinska Institutet